What Buyers Actually Look for During Due Diligence
When a buyer performs due diligence on a multi-site healthcare platform, they look at marketing through a specific and fairly unforgiving lens: is this a repeatable, scalable system, or is it dependent on individual talent and one-off campaigns? The answer to that question has a direct impact on how the business gets priced. Platforms with documented attribution infrastructure, declining CAC trends, and predictable same-site revenue contribution from marketing are treated as having a proven organic growth engine and priced accordingly. Platforms where marketing effectiveness can’t be demonstrated are treated as having an unproven growth driver. That uncertainty suppresses the multiple. Buyers don’t give credit for growth they can’t verify and can’t underwrite.
Why Organic Growth Commands a Higher Multiple Than Acquisition Growth
Not all growth is priced equally in multi-site healthcare transactions. Organic growth, same-site revenue increases driven by marketing, patient reactivation, and service mix improvement, commands a higher multiple than inorganic growth driven by acquisitions. The reason is straightforward: organic growth is scalable without proportional capital deployment. Acquisition-driven growth requires continued spending to sustain. When your marketing infrastructure demonstrably drives organic growth, you’re building something a buyer can underwrite and a lender can model. That’s a materially different asset than a revenue line that requires another acquisition to grow.
What an Exit-Ready Marketing Model Actually Looks Like
The phrase “exit-ready marketing” gets used loosely. What it means in practice is that the marketing function has three qualities a buyer can verify in the data room: the strategy and methodology are documented and accessible, not living in a departing CMO’s head; performance is attributable at the location level, so marketing’s contribution to financial outcomes can be shown specifically rather than claimed generally; and results are consistent across markets, demonstrating that the model scales without requiring reinvention at each new site. Of the three, attribution is typically the hardest to build and the most valuable to have. Most platforms can document their strategy. Far fewer can show, at the location level, which revenue increases in a given quarter trace back to specific marketing programs. That capability, when it exists and has been maintained over time, is what shifts the due diligence conversation from “tell us about your marketing” to “walk us through the model.” “Most platforms can document their strategy. Far fewer can show which revenue increases trace back to specific marketing programs and that gap is where multiples are won or lost.”
Three Capabilities That Show Up in Valuation
Attribution infrastructure that connects media spend to production outcomes gives buyers confidence that the growth model is understood and replicable, not contingent on a particular person or a favorable market. Documented CAC improvement over time signals that marketing is becoming more efficient as the organization scales, which is the direction buyers want to see. And campaign systems that perform consistently across locations demonstrate that the marketing engine runs systematically, not heroically. None of these is exotic. All of them require deliberate investment in measurement infrastructure before the transaction process begins which is why the two to three years leading up to a recap or sale are when these decisions matter most.
What the Marketing Story Looks Like in an Investment Memorandum
The marketing section of an investment memo typically needs to answer three questions for a buyer: How does this business acquire patients or clients? What does that acquisition cost, and is it improving? And what does marketing’s contribution to organic growth look like over time? The strongest versions of this section don’t just answer those questions, they answer them with trend data. Declining blended CAC over six to eight quarters. Same-site revenue contribution that’s consistent across location clusters, not just in a few top performers. De novo ramp timelines that have compressed as the marketing playbook has matured. That kind of longitudinal data tells a story a buyer can stress-test, which is exactly what elevates it from a marketing narrative to an underwriting input.
The Decisions That Matter in the Next 90 Days
If a recap or sale is somewhere in the next 18 to 36 months, the next 90 days are when the foundation gets set because the trend data buyers want to see takes time to build. A single quarter of strong CAC data is an anecdote. Six quarters of declining CAC is a pattern. The difference between those two things is whether you started 18 months ago. Three priorities worth moving on now: build or tighten the attribution infrastructure that connects marketing spend to location-level revenue outcomes, establish the CAC benchmarking cadence that will produce the trend line buyers look for, and start documenting same-site revenue contribution from marketing in a format that can be pulled directly into a data room. None of these takes 90 days to complete. But all of them take longer than 90 days to produce results worth showing. The marketing infrastructure that supports a compelling valuation story doesn’t get built during the transaction process, it gets built in the years before it. Agency Creative helps multi-site healthcare CMOs build it. Let’s start the conversation. Learn how Agency Creative can help boost your brand by calling us at 972.488.1660 or by contacting us online.
See More Work
